Evaluating TIMP-1, Ki67, and HER2 as markers for non-sentinel node metastases in breast cancer patients with micrometastases to the sentinel node

Tove Filtenborg Tvedskov; Annette Bartels; Maj-Britt Jensen; Birgitte Paaschburg; Niels Kroman; Eva Balslev; Nils Brünner

doi:10.1111/j.1600-0463.2011.02768.x

Evaluating TIMP-1, Ki67, and HER2 as markers for non-sentinel node metastases in breast cancer patients with micrometastases to the sentinel node

Tove Filtenborg Tvedskov, Annette Bartels, Maj-Britt Jensen, Birgitte Paaschburg, Niels Kroman, Eva Balslev, Nils Brünner

11 Citations (Scopus)

Abstract

Tvedskov TF, Bartels A, Jensen M-B, Paaschburg B, Kroman N, Balslev E, Brünner N. Evaluating TIMP-1, Ki67 and HER2 as markers for non-sentinel node metastases in breast cancer patients with micrometastases to the sentinel node. APMIS 2011; 119: 844-52. The aim was to investigate whether the biochemical prognostic markers TIMP-1, Ki67, and HER2 could predict metastatic spread to non-sentinel nodes (NSN) in breast cancer patients with micrometastases to sentinel node (SN). We included all breast cancer patients with micrometastases to SN operated between 2001 and 2007 at the Department of Breast Surgery, Herlev Hospital. The study was designed as a matched case-control study with 25 cases with micrometastases to SN and, in addition, metastatic spread to NSN and 50 matched controls with micrometastases to SN, but without NSN metastases. Patient and tumor characteristics were retrieved from the Danish Breast Cancer Cooperative Group database. Immunohistochemical analyses of TIMP-1 and Ki67 and measurements of HER2 on formalin-fixed paraffin-embedded tumor tissue were performed. No significant differences in the immunoreactivity of TIMP-1 and Ki67 were found between patients with and without NSN metastases. Six of seven HER2 positive patients did not have NSN metastases, but the results did not reach statistical significance. Despite being prognostic markers in breast cancer, TIMP-1 and Ki67 could not predict NSN metastases in women with micrometastatic disease to SN. Larger studies are needed to further validate HER2 as a marker for NSN metastases in these patients.

Original language	English
Book series	APMIS Supplementum
Volume	119
Issue number	12
Pages (from-to)	844-852
Number of pages	9
ISSN	0903-465X
DOIs	https://doi.org/10.1111/j.1600-0463.2011.02768.x
Publication status	Published - Dec 2011

Keywords

Adult
Aged
Breast Neoplasms
Female
Humans
Immunohistochemistry
Ki-67 Antigen
Lymphatic Metastasis
Middle Aged
Neoplasm Micrometastasis
Receptor, erbB-2
Sentinel Lymph Node Biopsy
Tissue Inhibitor of Metalloproteinase-1
Tumor Markers, Biological

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/j.1600-0463.2011.02768.x

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1600-0463.2011.02768.x

Cite this

Evaluating TIMP-1, Ki67, and HER2 as markers for non-sentinel node metastases in breast cancer patients with micrometastases to the sentinel node. / Tvedskov, Tove Filtenborg; Bartels, Annette; Jensen, Maj-Britt et al.

In: APMIS Supplementum, Vol. 119, No. 12, 12.2011, p. 844-852.

Research output: Contribution to journal › Journal article › Research › peer-review

@article{0169456c42d94dc0a3970141c717c419,

title = "Evaluating TIMP-1, Ki67, and HER2 as markers for non-sentinel node metastases in breast cancer patients with micrometastases to the sentinel node",

abstract = "Tvedskov TF, Bartels A, Jensen M-B, Paaschburg B, Kroman N, Balslev E, Br{\"u}nner N. Evaluating TIMP-1, Ki67 and HER2 as markers for non-sentinel node metastases in breast cancer patients with micrometastases to the sentinel node. APMIS 2011; 119: 844-52. The aim was to investigate whether the biochemical prognostic markers TIMP-1, Ki67, and HER2 could predict metastatic spread to non-sentinel nodes (NSN) in breast cancer patients with micrometastases to sentinel node (SN). We included all breast cancer patients with micrometastases to SN operated between 2001 and 2007 at the Department of Breast Surgery, Herlev Hospital. The study was designed as a matched case-control study with 25 cases with micrometastases to SN and, in addition, metastatic spread to NSN and 50 matched controls with micrometastases to SN, but without NSN metastases. Patient and tumor characteristics were retrieved from the Danish Breast Cancer Cooperative Group database. Immunohistochemical analyses of TIMP-1 and Ki67 and measurements of HER2 on formalin-fixed paraffin-embedded tumor tissue were performed. No significant differences in the immunoreactivity of TIMP-1 and Ki67 were found between patients with and without NSN metastases. Six of seven HER2 positive patients did not have NSN metastases, but the results did not reach statistical significance. Despite being prognostic markers in breast cancer, TIMP-1 and Ki67 could not predict NSN metastases in women with micrometastatic disease to SN. Larger studies are needed to further validate HER2 as a marker for NSN metastases in these patients.",

keywords = "Adult, Aged, Breast Neoplasms, Female, Humans, Immunohistochemistry, Ki-67 Antigen, Lymphatic Metastasis, Middle Aged, Neoplasm Micrometastasis, Receptor, erbB-2, Sentinel Lymph Node Biopsy, Tissue Inhibitor of Metalloproteinase-1, Tumor Markers, Biological, Micrometastases, sentinel node, TIMP-1, Ki67, HER2",

author = "Tvedskov, {Tove Filtenborg} and Annette Bartels and Maj-Britt Jensen and Birgitte Paaschburg and Niels Kroman and Eva Balslev and Nils Br{\"u}nner",

note = "{\textcopyright} 2011 The Authors. APMIS {\textcopyright} 2011 APMIS.",

year = "2011",

month = dec,

doi = "10.1111/j.1600-0463.2011.02768.x",

language = "English",

volume = "119",

pages = "844--852",

journal = "APMIS. Supplementum",

issn = "0903-465X",

publisher = "Wiley-Blackwell",

number = "12",

}

TY - JOUR

T1 - Evaluating TIMP-1, Ki67, and HER2 as markers for non-sentinel node metastases in breast cancer patients with micrometastases to the sentinel node

AU - Tvedskov, Tove Filtenborg

AU - Bartels, Annette

AU - Jensen, Maj-Britt

AU - Paaschburg, Birgitte

AU - Kroman, Niels

AU - Balslev, Eva

AU - Brünner, Nils

PY - 2011/12

Y1 - 2011/12

N2 - Tvedskov TF, Bartels A, Jensen M-B, Paaschburg B, Kroman N, Balslev E, Brünner N. Evaluating TIMP-1, Ki67 and HER2 as markers for non-sentinel node metastases in breast cancer patients with micrometastases to the sentinel node. APMIS 2011; 119: 844-52. The aim was to investigate whether the biochemical prognostic markers TIMP-1, Ki67, and HER2 could predict metastatic spread to non-sentinel nodes (NSN) in breast cancer patients with micrometastases to sentinel node (SN). We included all breast cancer patients with micrometastases to SN operated between 2001 and 2007 at the Department of Breast Surgery, Herlev Hospital. The study was designed as a matched case-control study with 25 cases with micrometastases to SN and, in addition, metastatic spread to NSN and 50 matched controls with micrometastases to SN, but without NSN metastases. Patient and tumor characteristics were retrieved from the Danish Breast Cancer Cooperative Group database. Immunohistochemical analyses of TIMP-1 and Ki67 and measurements of HER2 on formalin-fixed paraffin-embedded tumor tissue were performed. No significant differences in the immunoreactivity of TIMP-1 and Ki67 were found between patients with and without NSN metastases. Six of seven HER2 positive patients did not have NSN metastases, but the results did not reach statistical significance. Despite being prognostic markers in breast cancer, TIMP-1 and Ki67 could not predict NSN metastases in women with micrometastatic disease to SN. Larger studies are needed to further validate HER2 as a marker for NSN metastases in these patients.

AB - Tvedskov TF, Bartels A, Jensen M-B, Paaschburg B, Kroman N, Balslev E, Brünner N. Evaluating TIMP-1, Ki67 and HER2 as markers for non-sentinel node metastases in breast cancer patients with micrometastases to the sentinel node. APMIS 2011; 119: 844-52. The aim was to investigate whether the biochemical prognostic markers TIMP-1, Ki67, and HER2 could predict metastatic spread to non-sentinel nodes (NSN) in breast cancer patients with micrometastases to sentinel node (SN). We included all breast cancer patients with micrometastases to SN operated between 2001 and 2007 at the Department of Breast Surgery, Herlev Hospital. The study was designed as a matched case-control study with 25 cases with micrometastases to SN and, in addition, metastatic spread to NSN and 50 matched controls with micrometastases to SN, but without NSN metastases. Patient and tumor characteristics were retrieved from the Danish Breast Cancer Cooperative Group database. Immunohistochemical analyses of TIMP-1 and Ki67 and measurements of HER2 on formalin-fixed paraffin-embedded tumor tissue were performed. No significant differences in the immunoreactivity of TIMP-1 and Ki67 were found between patients with and without NSN metastases. Six of seven HER2 positive patients did not have NSN metastases, but the results did not reach statistical significance. Despite being prognostic markers in breast cancer, TIMP-1 and Ki67 could not predict NSN metastases in women with micrometastatic disease to SN. Larger studies are needed to further validate HER2 as a marker for NSN metastases in these patients.

KW - Adult

KW - Aged

KW - Breast Neoplasms

KW - Female

KW - Humans

KW - Immunohistochemistry

KW - Ki-67 Antigen

KW - Lymphatic Metastasis

KW - Middle Aged

KW - Neoplasm Micrometastasis

KW - Receptor, erbB-2

KW - Sentinel Lymph Node Biopsy

KW - Tissue Inhibitor of Metalloproteinase-1

KW - Tumor Markers, Biological

KW - Micrometastases

KW - sentinel node

KW - TIMP-1

KW - Ki67

KW - HER2

U2 - 10.1111/j.1600-0463.2011.02768.x

DO - 10.1111/j.1600-0463.2011.02768.x

M3 - Journal article

C2 - 22085360

SN - 0903-465X

VL - 119

SP - 844

EP - 852

JO - APMIS. Supplementum

JF - APMIS. Supplementum

IS - 12

ER -

Evaluating TIMP-1, Ki67, and HER2 as markers for non-sentinel node metastases in breast cancer patients with micrometastases to the sentinel node

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this